{"prompt": "['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '74', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'Based on existing clinical study data, most irAEs were reversible and could be managed with', 'interruptions of pembrolizumab, administration of corticosteroids and/or other supportive', 'care. For suspected irAEs, ensure adequate evaluation to confirm etiology or exclude other', 'causes. Additional procedures or tests such as bronchoscopy, endoscopy, skin biopsy may be', 'included as part of the evaluation. Based on the severity of irAEs, withhold or permanently', 'discontinue pembrolizumab and administer corticosteroids.', 'Modification and toxicity management guidelines for irAEs associated with pembrolizumab', 'monotherapy, coformulations, or IO combinations are provided in Table 3.', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '75', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'Table 3', 'Dose Modification and Toxicity Management Guidelines for Immune-related Adverse Events Associated with', 'Pembrolizumab Monotherapy, Coformulations or IO Combinations', 'General instructions:', '1. Severe and life-threatening irAEs should be treated with IV corticosteroids followed by oral steroids. Other immunosuppressive treatment', 'should', 'begin', 'if', 'the', 'irAEs are not controlled by corticosteroids.', '2. Pembrolizumab monotherapy, coformulations or IO combinations must be permanently discontinued if the irAE does not resolve or the corticosteroid dose', 'is not 10 mg/day within 12 weeks of the last treatment.', '3.', 'The corticosteroid taper should begin when the irAE is VI Grade 1 and continue at least 4 weeks.', '4. If pembrolizumab monotherapy, coformulations or IO combinations have been withheld, treatment may resume after the irAE decreased', 'to', 'VI', 'Grade', '1', 'after', 'corticosteroid taper.', 'Action With', 'Pembrolizumab', 'Monotherapy,', 'Toxicity Grade', 'Coformulations or', 'irAEs', '(CTCAEv4.0)', 'IO Combinations', 'Corticosteroid and/or Other therapies', 'Monitoring and Follow-up', 'Pneumonitis', 'Grade 2', 'Withhold', 'Administer corticosteroids (initial dose', 'Monitor participants for signs and symptoms of', 'of 1-2 mg/kg prednisone or', 'pneumonitis', 'equivalent) followed by taper', 'Evaluate participants with suspected pneumonitis', 'Recurrent Grade 2', 'Permanently', 'with radiographic imaging and initiate', 'or Grade 3 or 4', 'discontinue', 'corticosteroid treatment', 'Add prophylactic antibiotics for opportunistic', 'infections', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '76', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'Action With', 'Pembrolizumab', 'Monotherapy,', 'Toxicity Grade', 'Coformulations or', 'irAEs', '(CTCAEv4.0)', 'IO Combinations', 'Corticosteroid and/or Other therapies', 'Monitoring and Follow-up', 'Diarrhea/Colitis', 'Grade 2 or 3', 'Withhold', 'Administer corticosteroids (initial dose', 'Monitor participants for signs and symptoms of', 'of 1-2 mg/kg prednisone or', 'enterocolitis (ie, diarrhea, abdominal pain,', 'equivalent) followed by taper', 'blood or mucus in stool with or without fever)', 'and of bowel perforation (ie, peritoneal signs', 'and ileus)', 'Participants with Grade 2 diarrhea suspecting', 'Recurrent Grade 3', 'Permanently', 'colitis should consider GI consultation and', 'or Grade 4', 'discontinue', 'performing endoscopy to rule out colitis', 'Participants with diarrhea/colitis should be advised', 'to drink liberal quantities of clear fluids. If', 'sufficient oral fluid intake is not feasible, fluid', 'and electrolytes should be substituted via IV', 'infusion.', 'AST/ALT', 'Grade 2', 'Withhold', 'Administer corticosteroids (initial dose', 'Monitor with liver function tests (consider weekly', 'Elevation or', 'of 0.5-1 mg/kg prednisone or', 'or more frequently until liver enzyme value', 'Increased', 'equivalent) followed by taper', 'returned to baseline or is stable)', 'Bilirubin', 'Grade 3 or 4', 'Permanently', 'Administer corticosteroids (initial dose', 'discontinue', 'of 1-2 mg/kg prednisone or', 'equivalent) followed by taper', 'T1DM or', 'New onset T1DM', 'Withhold a', 'Initiate insulin replacement therapy for', 'Monitor participants for hyperglycemia or other', 'Hyperglycemia', 'or', 'participants with T1DM', 'signs and symptoms of diabetes', 'Grade 3 or 4', 'hyperglycemia', 'Administer antihyperglycemic in', 'associated with', 'participants with hyperglycemia', 'evidence of \u00df-cell', 'failure', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'Confidential']\n\n###\n\n", "completion": "END"}